BSE Live
Apr 10, 16:01Prev. Close
7.68
Open Price
7.66
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of DECIPHER LABS (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | |
| Per Share Ratios | ||||
| Basic EPS (Rs.) | 1.09 | 0.51 | 0.23 | |
| Diluted EPS (Rs.) | 1.09 | 0.51 | 0.23 | |
| Cash EPS (Rs.) | 1.64 | 0.51 | 0.23 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 12.44 | 3.16 | 2.65 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 12.44 | 3.16 | 2.65 | |
| Revenue from Operations/Share (Rs.) | 23.75 | 10.07 | 1.27 | |
| PBDIT/Share (Rs.) | 2.72 | 0.55 | 0.23 | |
| PBIT/Share (Rs.) | 2.17 | 0.55 | 0.23 | |
| PBT/Share (Rs.) | 1.45 | 0.55 | 0.23 | |
| Net Profit/Share (Rs.) | 1.09 | 0.51 | 0.23 | |
| NP After MI And SOA / Share (Rs.) | 1.09 | 0.51 | 0.23 | |
| Profitability Ratios | ||||
| PBDIT Margin (%) | 11.43 | 5.47 | 17.94 | |
| PBIT Margin (%) | 9.12 | 5.47 | 17.94 | |
| PBT Margin (%) | 6.11 | 5.47 | 17.94 | |
| Net Profit Margin (%) | 4.58 | 5.03 | 17.94 | |
| NP After MI And SOA Margin (%) | 4.58 | 5.03 | 17.94 | |
| Return on Networth/Equity (%) | 8.76 | 16.04 | 8.60 | |
| Return on Capital Employed (%) | 17.41 | 17.44 | 8.60 | |
| Return on Assets (%) | 3.11 | 6.39 | 6.15 | |
| Total Debt/Equity (X) | 0.90 | 0.08 | 0.06 | |
| Asset Turnover Ratio (%) | 67.79 | 127.05 | 34.31 | |
| Liquidity Ratios | ||||
| Current Ratio (X) | 0.99 | 1.66 | 3.52 | |
| Quick Ratio (X) | 0.98 | 1.57 | 3.40 | |
| Inventory Turnover Ratio (X) | 75.26 | 25.06 | 10.45 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | |
| Coverage Ratios | ||||
| Interest Coverage Ratios (%) | 3.03 | -- | -- | |
| Interest Coverage Ratios (Post Tax) (%) | 3.03 | -- | -- | |
| Valuation Ratios | ||||
| Enterprise Value (Cr.) | 28.85 | 19.90 | 16.27 | |
| EV/Net Operating Revenue (X) | 1.20 | 2.47 | 16.01 | |
| EV/EBITDA (X) | 10.51 | 45.09 | 89.20 | |
| MarketCap/Net Operating Revenue (X) | 0.79 | 2.48 | 15.90 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.52 | 7.92 | 7.62 | |
| Price/Net Operating Revenue | 0.79 | 2.48 | 15.91 | |
| Earnings Yield | 0.06 | 0.02 | 0.01 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth